Aragen Invests $30 million For Bio-manufacturing site in Bangalore

India Pharma Outlook Team | Tuesday, 31 October 2023

 India Pharma Outlook Team

Aragen, a leading contract research development and manufacturing organization (CRDMO) for small molecules and biologics, has announced the establishment of a new biologics manufacturing facility in Bangalore, India. The state-of-the-art facility is part of a $30 million investment covering nearly 160,000 square meters and includes process development laboratories and several GMP manufacturing facilities with support functions such as quality control laboratories (analytical and microbiology). The production facilities will be equipped for advanced processing using single-use bioreactors and advanced post-treatment capabilities to serve their own and rapidly growing biologics customers.

The facility offers integrated solutions of process development, process validation, analytical development, pilot production, and large-scale DS production and stability services. It has the ability to develop and manufacture mAbs, therapeutic proteins and fusion proteins to expand the company's bio manufacturing capabilities in California. "Aragen has been a leader in biologic drug discovery and development services, including cell line and antibody development, from our California location for nearly three decades. To date, our platform technology has enabled our partners to rapidly bring bio therapeutics to the clinic and several successful commercial products. The products of Aragen use CHO cell lines. With the opening of our bio manufacturing facility we offer our customers even faster development schedules and support their entire lifecycle journey from clone development to cell culture production , making Aragen a 'one-stop' solution provider for large molecules," commented Subodh Deshmukh. , CEO, Aragen Bioscience Inc. Manni Kantipudi, CEO of Aragen Life Sciences added the establishment of a biologics manufacturing facility in India is part of our future US-based biologics business integration strategy that will enable Aragen to provide our company with integrated GMP solutions

© 2024 India Pharma Outlook. All Rights Reserved.